Mr. Paul Levesque reports

THERATECHNOLOGIES JUNE 13 ONCOLOGY INVESTIGATOR CALL TO UPDATE INVESTORS & ANALYSTS ON PHASE 1 SUDOCETAXEL ZENDUSORTIDE TRIAL

Theratechnologies Inc. will hold a video conference call on Tuesday, June 13, 2023, to update investors and analysts on the phase 1 trial of its lead peptide-drug conjugate (PDC) candidate, sudocetaxel zendusortide (formerly TH1902), for the treatment of solid tumours.

During the call, Theratechnologies will provide insights on preliminary phase 1 safety and efficacy data that were presented at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO), as well as the United States Food and Drug Administration's (FDA) recent agreement to the company's amended phase 1 trial protocol. Both events are significant milestones in the development of sudocetaxel zendusortide, a PDC that targets the sortilin (SORT1) receptor, and a product of Theratechnologies' SORT1+ Technology platform.

Paul Levesque, president and chief executive officer of Theratechnologies, will host the call, which will feature presentations from Christian Marsolais, PhD, the company's senior vice-president and chief medical officer, as well as from investigators from the phase 1 trial. Presenters will be available to answer questions following prepared remarks.

Registration information

Title:  Oncology investigator call for investors and analysts: Phase 1 trial update

Date:  June 13, 2023

Time:  10 a.m. ET

Webcast:  access on-line

Dial-in:  1-888-317-6003 (toll-free) or 1-412-317-6061 (international)

Participant entry No.:  2792560

An archived webcast will also be available on the company's investor relations website under past events.

About SORT1+ Technology and sudocetaxel zendusortide (TH1902)

Theratechnologies has established its SORT1+ Technology platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumour types. SORT1 is a scavenger receptor that plays a significant role in protein internalization, sorting and trafficking. Expression of SORT1 is associated with aggressive disease, poor prognosis and decreased survival. It is estimated that SORT1 is expressed in 40 per cent to 90 per cent of endometrial, ovarian, colorectal, triple-negative breast (TNBC) and pancreatic cancers, making this receptor an attractive target for anti-cancer drug development.

Sudocetaxel zendusortide is a first-of-its-kind SORT1-targeting PDC, and the first compound to emerge from the SORT1+ Technology platform. A new chemical entity, sudocetaxel zendusortide employs a cleavable linker to conjugate (attach) a proprietary peptide to docetaxel, a well-established cytotoxic chemotherapeutic agent used to treat many cancers. The FDA granted fast track designation to sudocetaxel zendusortide as a single agent for the treatment of all sortilin-positive recurrent advanced solid tumours that are refractory to standard therapy. Sudocetaxel zendusortide is currently being evaluated in a phase 1 clinical trial.

About Theratechnologies Inc.

Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.

We seek Safe Harbor.